248 related articles for article (PubMed ID: 26481954)
1. Cancer specific risk in multiple sclerosis patients.
Kyritsis AP; Boussios S; Pavlidis N
Crit Rev Oncol Hematol; 2016 Feb; 98():29-34. PubMed ID: 26481954
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk among patients with multiple sclerosis: a population-based register study.
Nielsen NM; Rostgaard K; Rasmussen S; Koch-Henriksen N; Storm HH; Melbye M; Hjalgrim H
Int J Cancer; 2006 Feb; 118(4):979-84. PubMed ID: 16152598
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
4. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
Kingwell E; Bajdik C; Phillips N; Zhu F; Oger J; Hashimoto S; Tremlett H
Brain; 2012 Oct; 135(Pt 10):2973-9. PubMed ID: 22730559
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.
Amaria RN; Corboy JR; Finlayson CA; Robinson WA; Borges VF
Clin Breast Cancer; 2008 Oct; 8(5):449-52. PubMed ID: 18952560
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk among patients with multiple sclerosis and their parents.
Bahmanyar S; Montgomery SM; Hillert J; Ekbom A; Olsson T
Neurology; 2009 Mar; 72(13):1170-7. PubMed ID: 19332695
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic mechanisms of depression in multiple sclerosis.
Vattakatuchery JJ; Rickards H; Cavanna AE
J Neuropsychiatry Clin Neurosci; 2011; 23(3):261-76. PubMed ID: 21948887
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis.
Ghajarzadeh M; Mohammadi A; Sahraian MA
Autoimmun Rev; 2020 Oct; 19(10):102650. PubMed ID: 32801049
[TBL] [Abstract][Full Text] [Related]
11. [The role of the peripheral nervous system damage in clinical picture of multiple sclerosis].
Gusev EI; Lashch NIu; Boĭko AN; Demina TL
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):47-52. PubMed ID: 12938634
[TBL] [Abstract][Full Text] [Related]
12. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
13. Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study.
Sun LM; Lin CL; Chung CJ; Liang JA; Sung FC; Kao CH
Eur J Neurol; 2014 Feb; 21(2):238-44. PubMed ID: 24053223
[TBL] [Abstract][Full Text] [Related]
14. Malignant diseases among patients with multiple sclerosis.
Palo J; Duchesne J; Wikström J
J Neurol; 1977 Oct; 216(3):217-22. PubMed ID: 72140
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis preceding CNS lymphoma: a case report.
Yang JH; Wu SL
Acta Neurol Taiwan; 2007 Jun; 16(2):92-7. PubMed ID: 17685133
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS.
Ellwardt E; Zipp F
Exp Neurol; 2014 Dec; 262 Pt A():8-17. PubMed ID: 24530639
[TBL] [Abstract][Full Text] [Related]
17. Spinal cord injury is related to an increased risk of multiple sclerosis: a population-based, propensity score-matched, longitudinal follow-up study.
Lin CW; Huang YP; Pan SL
J Neurotrauma; 2015 May; 32(9):655-9. PubMed ID: 25545758
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Khan N; Woodruff TM; Smith MT
Pharmacol Biochem Behav; 2014 Nov; 126():13-27. PubMed ID: 25223977
[TBL] [Abstract][Full Text] [Related]
19. [Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy].
Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):86-93. PubMed ID: 31156246
[TBL] [Abstract][Full Text] [Related]
20. Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system.
Macchi B; Marino-Merlo F; Nocentini U; Pisani V; Cuzzocrea S; Grelli S; Mastino A
J Neuroimmunol; 2015 Oct; 287():80-7. PubMed ID: 26439966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
